$NVCR News

Novocure: A Mispriced Cash-Generating Biotech With Upside Potential

The Bull Case For NovoCure (NVCR) Could Change Following Japan’s Optune Pax Pancreatic Cancer Approval

Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer

Novocure to Report Third Quarter 2026 Financial Results

Japan’s Ministry Of Health, Labour And Welfare Approves Novocure's Optune Pax To Treat Adults With Unresectable Locally Advanced Pancreatic Cancer

NovoCure (NVCR) Stock Still Looks Cheap After Its 86% Fall

NovoCure (NVCR) Could Be 36% Undervalued Despite Its Recent Board Change

NovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-Even

NovoCure Limited (NVCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Wall Street Analysts See a 50.86% Upside in NovoCure (NVCR): Can the Stock Really Move This High?

Are You Looking for a Top Momentum Pick? Why NovoCure (NVCR) is a Great Choice

Wall Street Analysts Think NovoCure (NVCR) Could Surge 53.68%: Read This Before Placing a Bet

NovoCure (NVCR) Upgraded to Buy: What Does It Mean for the Stock?

Wall Street Analysts Believe NovoCure (NVCR) Could Rally 46.63%: Here's is How to Trade

Unlocking NovoCure (NVCR) International Revenues: Trends, Surprises, and Prospects

NovoCure (NVCR) Lifts 2026 Guidance After Record Quarter While Fair Value Debate Builds

NovoCure: Why I'm Fading The Q2 Earnings Rally

NovoCure Limited Q2 2026 Earnings Call Summary

NovoCure's Strongest Quarter Ever Isn't Enough to Stop NVCR Stock From Sliding

NovoCure's Clean Beat Signals A Shift Toward Profitability (Rating Upgrade)